Hepatitis C New Drugs Review
23.2K views | +1 today
Follow
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Virus-Induced Degradation of Cell Death-Inducing DFFA-Like Effector B Leads to Hepatic Lipid Dysregulation

Hepatitis C Virus-Induced Degradation of Cell Death-Inducing DFFA-Like Effector B Leads to Hepatic Lipid Dysregulation | Hepatitis C New Drugs Review | Scoop.it
RT @ASMicrobiology: Hepatitis C Virus degradation of CDIEB leads to hepatic lipid dysregulation #JVirology https://t.co/aGex4zmlE1 https://…

Our data demonstrate that HCV infection of human hepatocytes in vitro and in vivo results in CIDEB downregulation via a proteolytic cleavage event. Reduction of CIDEB protein levels by HCV or gene editing, in turn, leads to multiple aspects of lipid dysregulation, including LD stabilization. Consequently, CIDEB downregulation may contribute to HCV-induced hepatic steatosis.
Krishan Maggon 's insight:
Accepted manuscript posted online 10 February 2016, 
doi: 10.1128/JVI.02891-15 
J. Virol. April 2016 vol. 90 no. 8 4174-4185
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Differing perspectives on antiviral treatment efficacy in patients co-infected with HIV and HCV

Differing perspectives on antiviral treatment efficacy in patients co-infected with HIV and HCV | Hepatitis C New Drugs Review | Scoop.it
(European Association for the Study of the Liver) Two separate studies presented today at The International Liver Congress™ 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and hepatitis C virus (HCV).

Approximately 2.3 million people worldwide are co-infected with HIV and HCV1 

 April 13, 2016, Barcelona, Spain: Two separate studies presented today at The International Liver Congress™ 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV). GEHEP-SEIMC and HEPAVIR study group data: In this prospective, multi-cohort study from Spain, researchers have shown that HIV negatively impacts rates of response to DAA medications in people co-infected with HCV. Patients with HIV and HCV co-infection had an 11% lower rate of achieving SVR12 (or the eradication of HCV from the body at 12 weeks) with interferon-based DAAs compared to patients with only HCV. Those co-infected patients taking interferon-free DAAs had a 6% lower rate of achieving SVR12 compared to patients with only HCV.
Krishan Maggon 's insight:
International Liver Congress 2016 - Barcelona   EASL
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Evaluating the Challenges and Impact of Birth Cohort Screening for Hepatitis C in the Primary Care Clinic (Med-IQ)

Evaluating the Challenges and Impact of Birth Cohort Screening for Hepatitis C in the Primary Care Clinic (Med-IQ) | Hepatitis C New Drugs Review | Scoop.it
Improving the identification and management of patients with hepatitis C virus (HCV) is a critical goal and one that should be achieved in primary care. This publication provides an update of current medical literature regarding the prevalence of HCV, guidelines for birth cohort–based screening, and barriers to and best practices for improving the identification and management of patients with HCV in the primary care clinic.
Krishan Maggon 's insight:
Duke Univ.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study | Xie | Journal of the International AIDS Society

Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study | Xie | Journal of the International AIDS Society | Hepatitis C New Drugs Review | Scoop.it
Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study

Conclusions: HBV and HCV prevalence is high in HIV-positive Chinese and differs by geographic region. HBV and HCV co-infection and HIV monoinfection are risks for moderate-to-significant liver disease. Only HIV–HBV is associated with greater HIV-related immunosuppression. Incorporating screening and management of hepatitis virus infections into Chinese HIV programmes is needed. 

 Keywords: HIV; hepatitis B virus; hepatitis C virus; co-infection; prevalence; liver disease; CD4+ T cell count.
Krishan Maggon 's insight:
Xie J et al. Journal of the International AIDS Society 2016, 19:20659 http://www.jiasociety.org/index.php/jias/article/view/20659 | http://dx.doi.org/10.7448/IAS.19.1.20659
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma - Abdel-Rahman - 2016 - Cochrane Database of Systematic Reviews - Wiley Online Library

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma - Abdel-Rahman - 2016 - Cochrane Database of Systematic Reviews - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Cochrane: Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma https://t.co/caJFVyxsil insufficient evidence

Authors' conclusions There was insufficient evidence to assess the beneficial and harmful effects of yttrium-90 microsphere radioembolisation for people with unresectable hepatocellular carcinoma. Further randomised clinical trials are mandatory to better assess the potential beneficial and harmful outcomes of yttrium-90 microsphere trans-arterial radioembolisation either as a monotherapy or in combination with other systemic or locoregional therapies versus placebo, no treatment, or other systemic or locoregional therapies for people with unresectable hepatocellular carcinoma.
Krishan Maggon 's insight:
Cochrane Database of Systematic Reviews 

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma Review

Authors Omar M Abdel-Rahman, Zeinab Elsayed 

First published: 16 February 2016 Assessed as up-to-date: 22 January 2016 Editorial Group: Cochrane Hepato-Biliary Group 

DOI: 10.1002/14651858.CD011313.pub2
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Evaluation of Biofield Modality on Viral Load of Hepatitis B and C Viruses

Evaluation of Biofield Modality on Viral Load of Hepatitis B and C Viruses | Hepatitis C New Drugs Review | Scoop.it
By Mahendra Kumar Trivedi in Hepatitis C Virus and Hepatitis B virus. Study background: Nowadays, hepatitis is a major challenge for clinical research, regulatory bodies, and clinicians who are trying to assess the more effectiveness of antiviral
Krishan Maggon 's insight:
Trivedi et al., J Antivir Antiretrovir 2015, 7:3


Evaluation of Biofield Modality on Viral Load of Hepatitis B and C Viruses Mahendra Kumar Trivedi 1 , Shrikant Patil 1 , Harish Shettigar 1 , Sambhu Charan Mondal 2 and Snehasis Jana 2* 1Trivedi Global Inc., 10624 S Eastern Avenue Suite A-969, Henderson, NV 89052, USA2Trivedi Science Research Laboratory Pvt. Ltd., Hall-A, Chinar Mega Mall, Chinar Fortune City, Hoshangabad Rd., Bhopal- 462026, Madhya Pradesh, India * Corresponding author: Snehasis Jana, Trivedi Science Research Laboratory Pvt. Ltd., Hall-A, Chinar Mega Mall, Chinar Fortune City, Hoshangabad Rd.,Bhopal-462026, Madhya Pradesh, India, Tel: +91-755-6660006; 

E-mail: publication@trivedisrl.com Received date: June 29, 2015; Accepted date: July 17, 2015; Published date: July 24, 201
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

This is the most expensive drug in America

This is the most expensive drug in America | Hepatitis C New Drugs Review | Scoop.it
Gilead’s hepatitis C drugs Sovaldi and Harvoni top the list of America’s most expensive prescription drugs.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Understanding the Magnitude of the Viral Hepatitis Epidemics in the United States

Understanding the Magnitude of the Viral Hepatitis Epidemics in the United States | Hepatitis C New Drugs Review | Scoop.it
In March I had the honor of meeting with an inspirational group of advocates, leaders and researchers who had come to Washington to educate lawmakers about viral hepatitis and its impact on our nation. Their braveness and authenticity was moving. They told their personal stories about living with viral hepatitis, the frustrating experiences wit

The CDC website currently states that an estimated 2.7 million to 3.9 million people in the United States are living with chronic hepatitis C virus (HCV) infection. Another 700,000 to 1.4 million people are living with chronic hepatitis B virus (HBV) infection. If we add these together, ignoring the number of persons coinfected with HBV and HCV, this suggests that there are roughly 3.4 million to 5.3 million people living with viral hepatitis in the United States. That’s a lot of people. These women, men, and children are at risk for developing severe liver disease if they do not get effective treatment and potentially transmitting the infection to others. Some estimates are even higher.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Advisory Panel Backs Intercept’s Liver Drug, FDA Ruling up Next

Advisory Panel Backs Intercept’s Liver Drug, FDA Ruling up Next | Hepatitis C New Drugs Review | Scoop.it
A panel of FDA advisors gave a thumbs-up today to obeticholic acid, a drug from New York-based Intercept Pharmaceuticals (NASDAQ: ICPT) that the agency is considering as a treatment for a rare autoimmune liver disease. The outside advisors, mainly medical specialists from around the U.S., recommended that the FDA approve obeticholic acid, or OCA, by […]
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

JAMA Forum: We Can’t All Have It All: The Economic Limits of Pharmaceutical Innovation

JAMA Forum: We Can’t All Have It All: The Economic Limits of Pharmaceutical Innovation | Hepatitis C New Drugs Review | Scoop.it
Even though US consumers spend 3 times more for hospital care than for medication, they are much angrier with pharmaceutical companies than hospitals for driving up the cost of health care. Drug companies raise this apparent inconsistency in an effort to defend their pricing practices. In so doing, however, they fail to appreciate why they’ve…
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016...

AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016... | Hepatitis C New Drugs Review | Scoop.it
RT @abbvie: We are ready for a busy #ILC2016 expanding scientific knowledge of #HepC. Read more: https://t.co/cml5TEvsxp

NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress™ (ILC) 2016 in Barcelona, Spain, April 13-17, including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated cirrhosis (Child-Pugh A). Additionally, data will be presented from AbbVie's HCV pipeline program, investigating its pan-genotypic, once-daily, ribavirin-free regimen of ABT-493 and ABT-530 in patients with genotypes 1-6 (GT1-6) chronic HCV infection, including data on treatment durations of as short as eight weeks in genotypes 1-3 (GT1-3) treatment-naïve patients without cirrhosis.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success? - Sáez-Royuela - Liver International - Wiley Online Library

Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success? - Sáez-Royuela - Liver International - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a ... https://t.co/Vlv0jKPQnT
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies ...

A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies ... | Hepatitis C New Drugs Review | Scoop.it
Background and Aim
Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in interferon (±ribavirin)-ineligible or -intolerant Asian patients with genotype 1b infection from mainland China, Korea, and Taiwan.
Methods
Interferon (±ribavirin)-ineligible and -intolerant patients with genotype 1b infection received daclatasvir 60 mg tablets once-daily plus asunaprevir 100 mg soft capsules twice-daily for 24 weeks. The primary endpoint was sustained virologic response at post-treatment Week 24 (SVR24).
Results
Of the 159 patients treated, 89.3% were Chinese, 65.4% were female, and 73.6% were interferon-intolerant. Cirrhosis was present in 32.7% of patients and 40.3% had IL28B non-CC genotypes. SVR24 was achieved by 145/159 (91.2%) patients (100% concordance with SVR12) and was similarly high in cirrhotic patients (47/52, 90.4%). SVR24 was higher in patients without baseline NS5A (L31M or Y93H) resistance-associated variants (RAVs) (137/139, 98.6%), including those with cirrhosis (43/44, 97.7%). Prevalence of baseline NS5A RAVs was low (19/159, 11.9%), particularly in mainland China (10/127, 7.9%). One death (0.6%), five serious adverse events (3.1%), and three grade 4 laboratory abnormalities (1.9%) occurred on-treatment; none were considered related to study drugs. Two patients (1.3%) discontinued due to adverse events. Treatment was generally well-tolerated regardless of cirrhosis status.
Conclusions
Daclatasvir plus asunaprevir achieved a SVR24 rate of 91.2%, rising to 98.6% in patients without baseline NS5A RAVs, and was generally well tolerated in interferon (±ribavirin)-ineligible or -intolerant patients with genotype 1b infection from mainland China, Korea, and Taiwan. This article is protected by copyright. All rights reserved.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

High rate of cancer recurrence found in certain hepatitis C patients

High rate of cancer recurrence found in certain hepatitis C patients | Hepatitis C New Drugs Review | Scoop.it
(European Association for the Study of the Liver) Data from a new study show that patients with hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer had a 'high rate' of re-developing their illness.

April 13, 2016, Barcelona, Spain: Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver cancer,1 had a ‘high rate’ of re-developing their illness. The large retrospective cohort study, presented today at The International Liver CongressTM in Barcelona, Spain found 29% of patients who had a history of HCC re-developed the condition during or after taking DAAs.
Krishan Maggon 's insight:
EASL  The International Liver Congress™ 2016
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Massive whole-genome study finds six types of liver cancer

Massive whole-genome study finds six types of liver cancer | Hepatitis C New Drugs Review | Scoop.it
In the largest genomic study ever targeting single-organ cancers, Japanese researchers have completed a whole-genome analysis of 300 liver cancer patients, discovering that liver cancer among Japanese can be broken down into six types. The study, jointly carried out by a number of institutions including the National Cancer Center, the Riken research institute and the […]
The post Massive whole-genome study finds six types of liver cancer appeared first on The Japan Times.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report

Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report | Hepatitis C New Drugs Review | Scoop.it
Download a PDF of "Eliminating the Public Health Problem of Hepatitis B and C in the United States" by the National Academies of Sciences, Engineering, and Medicine for free. Description: Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world’s hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide.

The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Korean Dong A ST bets $75 millions on Tobira Therapeutics  Evogliptin and Cenicriviroc (CVC) for NASH 

Korean Dong A ST bets $75 millions on Tobira Therapeutics  Evogliptin and Cenicriviroc (CVC) for NASH  | Hepatitis C New Drugs Review | Scoop.it

Tobira is currently enrolling patients in CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more information about the CENTAUR study, visit www.clinicaltrials.gov, trial identifier NCT02217475.


SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, April 11, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) and Dong-A ST Co., Ltd. (170900: Korea SE), today announced that the companies have entered into two separate licensing agreements. Tobira has acquired exclusive rights to develop and market evogliptin in combination with cenicriviroc (CVC) and as a single agent in the United States, Canada, Europe and Australia for all therapeutic indications. Dong-A has received an exclusive license to develop and market CVC, as both a single agent and in combination with evogliptin in the Republic of Korea for all therapeutic indications. Both companies plan to initiate development programs for the combination of the two agents for the treatment of patients with non-alcoholic steatohepatitis (NASH) and also plan to collaborate on a global Phase 3 program for CVC single agent for NASH. 


 Under the terms of the agreement, Dong-A received an upfront cash payment of $1.5 million and is eligible to receive up to an additional $25 million in payments linked to the achievement of Phase 3 completion and approval milestones for the first indication and up to an additional $10 million for additional indications. Dong-A may receive up to an additional $35 million for commercial milestones. Tobira received an upfront cash payment of $0.5 million and is eligible to receive up to an additional $2.5 million in payments linked to the achievement of similar milestones per indication in the Republic of Korea. In addition, each party will receive tiered royalty payments based on net sales. Each company is responsible for its own development costs incurred within its respective territory.

Krishan Maggon 's insight:
CVC in NASH CVC is a dual inhibitor of the CCR2 and CCR5 pathways which play a key role in the cycle of inflammation and fibrosis. CVC has been shown in clinical trials to bind to both CCR2 and CCR5 targets and has been studied to date inapproximately 580 subjects treated in human clinical trials[PL1]. In June 2015, Tobira completed enrollment in CENTAUR, a global randomized Phase 2 study of CVC vs placebo in patients with NASH and liver fibrosis. For more information about the CENTAUR study, visit www.clinicaltrials.gov, trial identifier NCT02217475.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti–hepatitis C target

A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti–hepatitis C target | Hepatitis C New Drugs Review | Scoop.it
#Science https://t.co/iRYKw9ZVuH ;

Abstract G-quadruplex (G4) is one of the most important secondary structures in nucleic acids. Until recently, G4 RNAs have not been reported in any ribovirus, such as the hepatitis C virus. Our bioinformatics analysis reveals highly conserved guanine-rich consensus sequences within the core gene of hepatitis C despite the high genetic variability of this ribovirus; we further show using various methods that such consensus sequences can fold into unimolecular G4 RNA structures, both in vitro and under physiological conditions. Furthermore, we provide direct evidences that small molecules specifically targeting G4 can stabilize this structure to reduce RNA replication and inhibit protein translation of intracellular hepatitis C. Ultimately, the stabilization of G4 RNA in the genome of hepatitis C represents a promising new strategy for anti–hepatitis C drug development. 

Keywords    guanine-rich consensus sequence, targeting G-quadruplex, RNA
Krishan Maggon 's insight:
Science Advances Vol 2, No. 4 01 April 2016

Shao-Ru Wang1,*, Yuan-Qin Min2,*, Jia-Qi Wang1, Chao-Xing Liu1, Bo-Shi Fu1, Fan Wu1, Ling-Yu Wu1, Zhi-Xian Qiao3, Yan-Yan Song1, Guo-Hua Xu4, Zhi-Guo Wu5, Gai Huang5, Nan-Fang Peng5, Rong Huang1, Wu-Xiang Mao1, Shuang Peng1, Yu-Qi Chen1, Ying Zhu5, Tian Tian1,†, Xiao-Lian Zhang2,† and Xiang Zhou1,† 

1College of Chemistry and Molecular Sciences, Key Laboratory of Biomedical Polymers of Ministry of Education, Wuhan University, Wuhan 430072, Hubei, China. 2State Key Laboratory of Virology and Hubei Province Key Laboratory of Allergy and Immunology and Department of Immunology, School of Medicine, Wuhan University, Wuhan 430071, Hubei, China. 3Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, Hubei, China. 4Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan 430071, Hubei, China. 5College of Life Sciences, Wuhan University, Wuhan 430072, Hubei, China. ↵

†Corresponding author. E-mail: xzhou@whu.edu.cn (X.Z.); zhangxiaolian@whu.edu.cn (X.-L.Z.); ttian@whu.edu.cn (T.T.) ↵* These authors contributed equally to this work. 

Science Advances 01 Apr 2016: Vol. 2, no. 4, e1501535 

DOI: 10.1126/sciadv.1501535 Article
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Bracco Diagnostics’ Lumason ultrasound contrast agent gets FDA approval

Bracco Diagnostics’ Lumason ultrasound contrast agent gets FDA approval | Hepatitis C New Drugs Review | Scoop.it
The US Food and Drug Administration (FDA) has granted approval for the US-based subsidiary of Bracco Imaging, Bracco Diagnostics' Lumason for ultrasonography of the liver.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department

Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department | Hepatitis C New Drugs Review | Scoop.it
#Infections Evaluation of the Centers for Disease Control and Prevention Recommendations for… https://t.co/CZEtOh7ePr

Conclusions. Birth cohort–based testing would augment identification of undocumented HCV infections in this ED 2-fold, relative to risk-based testing only. However, our data demonstrate that one-quarter of infections would remain undiagnosed if current CDC birth cohort recommendations were employed, suggesting that in high-risk urban ED settings a practice of universal 1-time testing might be more effective. 


 Key words HCV emergency department undiagnosed infection HCV testing CDC recommendations
Krishan Maggon 's insight:
Clin Infect Dis. (2016) 62 (9): 1059-1065. doi: 10.1093/cid/ciw074 First published online: February 21, 2016
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The Top Infectious Disease Stories of 2015

The Top Infectious Disease Stories of 2015 | Hepatitis C New Drugs Review | Scoop.it
There are a plethora of infectious disease (ID) stories in the news that can have important medical consequences.

It is rare that such a significant viral illness has been potentially defeated so quickly. It is estimated that there are 453,000 people in the United States infected with HCV and 130-175 million worldwide.8 Cure rates of over 95% have been seen with oral agents administered for 8 weeks. The major controversy now is the cost of these medications, many patients with HCV infection cannot afford them. These drugs may be cost-effective by preventing the need for liver transplants and other medical comorbidities but who will pay the upfront cost.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

NASH Drugs: A Comprehensive Review Of Current Clinical Trials

NASH Drugs: A Comprehensive Review Of Current Clinical Trials | Hepatitis C New Drugs Review | Scoop.it
NASH has no FDA-approved therapy and could represent a $35 billion market by 2025, prompting many biotechs to race for the approval of the first NASH-targeted d
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

WHO | Hepatitis A

WHO | Hepatitis A | Hepatitis C New Drugs Review | Scoop.it
Hepatitis A: WHO fact sheet on hepatitis A provides key facts, transmission, who is at risk, treatment, prevention, immunization, WHO response.
Krishan Maggon 's insight:
WHO  World health Day
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti–hepatitis C target

A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti–hepatitis C target | Hepatitis C New Drugs Review | Scoop.it
A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti–hepatitis C target
Krishan Maggon 's insight:
A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti–hepatitis C target Shao-Ru Wang1,*, Yuan-Qin Min2,*, Jia-Qi Wang1, Chao-Xing Liu1, Bo-Shi Fu1, Fan Wu1, Ling-Yu Wu1, Zhi-Xian Qiao3, Yan-Yan Song1, Guo-Hua Xu4, Zhi-Guo Wu5, Gai Huang5, Nan-Fang Peng5, Rong Huang1, Wu-Xiang Mao1, Shuang Peng1, Yu-Qi Chen1, Ying Zhu5, Tian Tian1,†, Xiao-Lian Zhang2,† and Xiang Zhou1,† + Author Affiliations ↵†Corresponding author. E-mail: xzhou@whu.edu.cn (X.Z.); zhangxiaolian@whu.edu.cn (X.-L.Z.); ttian@whu.edu.cn (T.T.) ↵* These authors contributed equally to this work. Science Advances 01 Apr 2016: Vol. 2, no. 4, e1501535 DOI: 10.1126/sciadv.1501535
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals - Chhatwal - 2016 - Hepatology - Wiley Online Library

Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals - Chhatwal - 2016 - Hepatology - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
RT @HEP_Journal: Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals https://t.co/T8wwAk3CAJ #AASLD…
more...
No comment yet.